| First character of title | Commenter | Comment Information |
A
|
Title: MD
Organization: UPMC, Hillman Cancer Center
Date: 06/15/2018
Comment:
The new immunotherapy treatment CAR-T represent a paradigm change in cancer therapy. For the first time, cancer treatment can be directed specifically to the cancer cells, sparing most of the normal cells, and resulting in very high remission
More opens in new window
|
|
Title: President and CEO
Organization: Friends of Cancer Research
Date: 06/15/2018
Comment:
Jeff Allen, PhD
1800 M Street NW
Suite 1050 South
Washington, DC 20036
June 15, 2018
Tamara Syrek Jensen, JD
Director, Coverage and Analysis Group
Center for Clinical Standards and Quality
Centers for
More opens in new window
|
|
Title: Patient Access
Organization: MDACC
Date: 06/11/2018
Comment:
After two failed therapies, the patients are desperate for a life saving treatment, that is, the disease is so aggressive that there's a sense of urgency to save their lives. Considering this treatment as a covered benefit will help a lot of
More opens in new window
|
B
|
Title: Executive Vice President
Organization: Celgene Corporation
Date: 06/15/2018
Comment:
Tamara Syrek Jensen
Director, Evidence and Analysis Group
Center for Clinical Standards and Quality
Centers for Medicare & Medicaid Services
7500 Security Boulevard
S3-02-01
Baltimore, Maryland 21244
More opens in new window
|
|
Title: Chief Medical Officer
Organization: America’s Health Insurance Plans (AHIP)
Date: 06/14/2018
Comment:
America’s Health Insurance Plans (AHIP) appreciates the opportunity to comment on the national coverage analysis for CAR T-Cell Therapy for Cancers.
We agree with the requestor that a national coverage determination may be useful for
More opens in new window
|
|
Title: Board Member and Patient Caregiver
Organization: MPN Research Foundation
Date: 06/14/2018
Comment:
I urge that CAR T-cell therapy be covered by Medicare.
CAR T therapy is a very promising approach to treating Primary Myleofibrosis, a disease [PHI Redacted] suffers from. She faces a likely choice in the next couple
More opens in new window
|
|
Title: Senior Vice President, Public Policy
Organization: Personalized Medicine Coalition
Date: 06/15/2018
Comment:
June 15, 2018
Tamara Syrek Jensen, J.D.
Director, Coverage & Analysis Group
Centers for Medicare & Medicaid Services
Mailstop S3-02-01
7500 Security Blvd.
Baltimore, MD 21244
Sent
More opens in new window
|
|
Title: Director, Health Policy and Regulatory Compliance
Organization: BJC HealthCare
Date: 06/15/2018
Comment:
Thank you for this opportunity to comment on this National Coverage Analysis for Chimeric Antigen Receptor (CAR) T-cell therapies. BJC HealthCare, our member teaching institution, Barnes-Jewish Hospital, and our physician partners at the
More opens in new window
|
|
Title: Executive Director
Organization: Alliance of Dedicated Cancer Centers (ADCC)
Date: 06/15/2018
Comment:
June 15, 2018
Ms. Seema Verma
Administrator
Centers for Medicare & Medicaid Services
Department of Health and Human Services
Hubert H. Humphrey Building
Room 445-G
200 Independence Avenue, NW
Washington,
More opens in new window
|
|
Title: Policy and Practice Manager
Organization: American Society of Hematology
Date: 06/14/2018
Comment:
June 15, 2018
Tamara Syrek Jensen, JD, Director
Evidence and Analysis Group
Centers for Medicare & Medicaid Services
7500 Security Boulevard
Baltimore, MD 21244
Katherine B. Szarama, PhD, Lead
More opens in new window
|
C
|
Title: President & Physician-in-Chief
Organization: City of Hope National Medical Center
Date: 06/15/2018
Comment:
As the Physician-in-Chief at The City of Hope National Medical Center (COH), and the President of Strategy and Business Ventures, we welcome the opportunity to submit comments on behalf of our institution regarding the National Coverage Analysis
More opens in new window
|
|
Title: Professor, Medical Oncology
Organization: Sidney Kimmel Cancer Center Thomas Jefferson University
Date: 06/15/2018
Comment:
June 15, 20018
Re: National Coverage Analysis for Chimeric Antigen Receptor (CAR) T-cell Therapy for Cancers (CAG-00451N)
Dear Administrator Verma, Ms. Jensen and Drs. Szarama and Paserchia:
The Sidney Kimmel Cancer Center
More opens in new window
|
|
Title: Chief Executive Officer
Organization: National Comprehensive Cancer Network
Date: 06/15/2018
Comment:
June 15, 2018
Tamara Syrek Jensen, JD, Director
Evidence and Analysis Group
Centers for Medicare & Medicaid Services
7500 Security Boulevard
Baltimore, MD 21244
RE: National Coverage Analysis (NCA) Tracking Sheet
More opens in new window
|
|
Organization: College of American Pathologists
Date: 06/15/2018
Comment:
June 15, 2018
Tamara Syrek Jensen, JD, Director
Evidence and Analysis Group
Centers for Medicare & Medicaid Services
7500 Security Boulevard
Baltimore, MD 21244
Katherine B. Szarama, PhD, Lead Analyst
Evidence
More opens in new window
|
|
Title: Director, Federal Relations
Organization: Vanderbilt University Medical Center
Date: 06/15/2018
Comment:
June 15, 2018
Tamara Syrek Jensen, JD, Director
Evidence and Analysis Group
Centers for Medicare & Medicaid Services
7500 Security Boulevard
Baltimore, MD 21244
Katherine B. Szarama, PhD, Lead Analyst
Evidence
More opens in new window
|
D
|
Title: Senior Specialty Billing Analyst RN
Organization: Piedmont Healthcare
Date: 05/24/2018
Comment:
As a veteran of our country's health care system I endorse and support the approval of a National Coverage Determination for CAR T-cell Therapy for cancers where the clinical trial outcomes support such a therapy. My career spans over 45 years,
More opens in new window
|
E
|
Title: Chair Cellular Therapy
Organization: The US Oncology Network
Date: 06/15/2018
Comment:
Chimeric Antigen Receptor therapy (CAR-T) is a significant advancement in the treatment of cancer. This is a living cellular therapy using the patient’s own T cells and transforming them in the laboratory to fight the malignant cells. The cells
More opens in new window
|
F
|
Title: Director, U.S. Policy and Advocacy
Organization: Alliance for Regenerative Medicine
Date: 06/15/2018
Comment:
June 15, 2018
Katherine B. Szarama, PhD
Lead Analyst
Coverage and Analysis Group
Centers for Medicare & Medicaid Services
Department of Health and Human Services
7500 Security Blvd.
Baltimore, MD 21244
More opens in new window
|
|
Title: Director, Health Policy and Strategic Relations
Organization: American Society for Blood and Marrow Transplantation
Date: 06/14/2018
Comment:
RE: Chimeric Antigen Receptor (CAR) T-cell Therapy for Cancers
CAG-00451N
Ms. Syrek Jensen and Drs. Szarama and Paserchia:
The American Society for Blood and Marrow Transplantation (ASBMT), the Center for
More opens in new window
|
|
Title: Manager, Revenue Integrity
Organization: Duke Health
Date: 06/15/2018
Comment:
June 15, 2018
Tamara Syrek Jensen, Director
Evidence and Analysis Group
Centers for Medicare & Medicaid Services
7500 Security Boulevard
Baltimore, MD 21244
Katherine B. Szarama, PhD, Lead Analyst
Evidence
More opens in new window
|
|
Title: Strategic Alliance Manager
Organization: American Society of Gene & Cell Therapy
Date: 06/15/2018
Comment:
Tamara Syrek Jensen, JD, Director
Evidence and Analysis Group
Centers for Medicare & Medicaid Services
7500 Security Boulevard
Baltimore, MD 21244
Katherine B. Szarama, PhD, Lead Analyst
Evidence and Analysis
More opens in new window
|
G
|
Title: Stem Cell Transplant Clinical Pharmacist
Organization: Vanderbilt University Medical Center
Date: 06/14/2018
Comment:
I have major concerns with using NCD to resolve a financial contracting issue specific to the Medicare Advantage plans, as it has such strong potential to hinder access to CAR-T for those that need the therapy. Kymriah and Yescarta are medically
More opens in new window
|
|
Title: Chief Attending, Adult BMT Service
Organization: Memorial Sloan Kettering Cancer Center
Date: 06/14/2018
Comment:
June 13, 2018
Ms. Seema Verma
Administrator, Centers for Medicare & Medicaid Services
Department of Health and Human Services
Hubert H. Humphrey Building, Rm 445-G
200 Independence Avenue, NW
Washington, DC
More opens in new window
|
|
Title: Direc
Organization: American Society of Clinical Oncology
Date: 06/15/2018
Comment:
Via Electronic Submission
June 15, 2018
Tamara Syrek Jensen, JD, Director
Evidence and Analysis Group
Centers for Medicare & Medicaid Services
7500 Security Boulevard
Baltimore, MD 21244
Katherine B. Szarama,
More opens in new window
|
|
Title: Unrelated donor program director, MM program direc
Organization: Colorado Blood Cancer Institute
Date: 06/14/2018
Comment:
Re: National Coverage Analysis for Chimeric Antigen Receptor (CAR) T-cell Therapy for Cancers (CAG-00451N)
Dear Administrator Verma, Ms. Jensen and Drs. Szarama and Paserchia:
Colorado Blood Cancer Institute is the largest blood
More opens in new window
|
